Navigation Links
Top Ranked Equity Analyst Joins Vital Therapies, Inc.
Date:3/19/2012

SAN DIEGO, March 19, 2012 /PRNewswire/ -- Vital Therapies, Inc., a development stage biotechnology company focused on allogeneic cellular therapy for acute liver failure, today announced that it has appointed Duane Nash, MD, JD, MBA, as the company's Chief Business Officer and Medical Director. Dr. Nash joins Vital Therapies, Inc., from Wedbush PacGrow Life Sciences where he was Senior Vice President in Equity Research. According to STARMINE® / Thomson Reuters, Dr. Nash is currently ranked first among 66 equity research analysts nationwide who publish in the biotechnology market, based on prior 12 month return on recommendations.    

Dr. Nash received a BA in Biology from Williams College, an MD from Dartmouth Medical School, a JD from the University of California at Berkeley, and an MBA from the University of Oxford.  He completed his internship in General Surgery at the University of California at San Francisco, where he served as a member of the liver transplant team.  Dr. Nash also practiced as an attorney for six years, most recently at the law firm of Davis Polk, where he focused on intellectual property litigation and corporate matters.  

"Liver failure poses a staggering unmet need both in the United States and worldwide," said Dr. Nash.  "Fortunately, Vital Therapies' ELAD® has shown unique promise, with preliminary data suggesting it may improve survival among patients with acute liver failure.  I'm honored to play a role in the company's upcoming pivotal trials where we hope to confirm preliminary findings, and also in ELAD's subsequent commercialization."    

"We are delighted Dr. Nash is joining our program to commercialize ELAD in USA, EU and worldwide," said Terry Winters, PhD, Vital Therapies, Inc.'s Chairman and Chief Executive Officer. "His unique mix of skills and experience in the life sciences will be invaluable in helping to transition the company to the public markets and in implementing our upcoming pivotal studies for marketing approval. His intimate knowledge of both clinical practice for liver disease and the breadth of new technologies under development is a compliment to the potential of ELAD in liver therapy."

About Vital Therapies, Inc.

Vital Therapies, Inc. is a private development-stage biotechnology company based in San Diego, California.  The company is developing ELAD®, an extracorporeal liver support system which functions by processing toxins and synthesizing proteins and metabolites that are the key processes of normal human liver function, and represents the first human allogeneic cellular therapy for acute liver failure.  Vital Therapies has completed seven clinical trials including a pivotal trial in China, which was used to file for marketing approval in China and which remains pending.  A US/EU pivotal trial plan to secure BLA and MAA approval has received written guidance from FDA and EMA. The first protocol under this plan, for a survival trial in acute alcoholic hepatitis, has been allowed by FDA. The trial should start soon.

About ELAD

ELAD is a bedside system whose central component is four cartridges containing 440 grams of immortalized human liver cells and 32,000 hollow fibers.  The patient's plasma flows inside of the hollow fibers to allow two-way transfer of metabolites.  During ELAD therapy the cells metabolize toxins and synthesize proteins and other liver specific products essential for life. The ELAD cell cartridges are produced at VTI's GMP-compliant facility in San Diego, California.

ELAD is a trademark of Vital Therapies, Inc.

STARMINE is a trademark of Thomson Reuters


'/>"/>
SOURCE Vital Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
3. RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas-Fort Worth Area
4. RealMed Ranked as 2009 Best in KLAS Claims and Clearinghouse Service
5. BMP Sunstones Hao Wawa (Good Baby) Brand Ranked First Among Chinas Top Three Pediatric Medicine Brands
6. Healthcare Communications Group Ranked on the 2010 Inc. 5000
7. eCardio Ranked as One of Houstons Fastest Growing Companies
8. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
9. Genoptix Ranked 41st Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
10. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):